Catalyzing Innovation in TB Care: Solutions During COVID-19 and Beyond
The COVID-19 pandemic is wreaking havoc around the world – and taking a particularly devastating toll on the health of the most vulnerable, including those living with drug-resistant tuberculosis (DR-TB). Patients and survivors with respiratory impairment and/or lung damage may be more vulnerable to serious complications from COVID-19. Beyond individual vulnerability, the COVID-19 pandemic has seriously disrupted and weakened already-fragile systems of delivering care to people with DR-TB. A recent modeling study estimated that national lockdowns and gradual restoration measures required to contain the COVID-19 pandemic could lead to an additional 6.3 million TB cases and 1.4 million TB deaths by 2025.(1)
Collective action is urgently to help ensure continuity of care for people with DR-TB during the pandemic. In particular, innovative solutions at the community level could help people with DR-TB connect with healthcare providers, ensure they have sufficient supply of medicines, and access peer-to-peer support – all without leaving their homes.
Join us on September 16th for a discussion on how innovators and entrepreneurs from around the world are stepping up and sharing their opinions on how to address this public health challenge. A panel of experts, including a TB survivor, will discuss their views on how creative solutions to the challenges being faced by DR-TB patients can be scaled up with the aim to reach those in need. Awardees of Johnson & Johnson’s DR-TB Lifeline Quickfire Challenge will be announced and will share how their innovations could help ensure people with DR-TB receive the care they need during this unprecedented time.